Date: 2014-04-28
Type of information: Subvention
Company: PROTEVIH consortium : Innavirvax (France), Diaxonhit, INSERM-Université Paris-Sud/CESP / U1018 at Hôpital Kremlin Bicêtre, INSERM-Université de Bordeaux Segalen / ISPED - UMR 897
Investors: Bpifrance (France)
Amount: €9.4 million
Funding type: subsidies and refundable advance payments
Planned used: The PROTHEVIH programme (PROTECTION of the immune system by DIAGNOSIS and personalised THERAPY targeting the pathogenicity of HIV) aims to respond to unsatisfied medical needs among HIV-infected patients. The consortium seeks to accelerate the development of three solutions resulting from InnaVirVax\'s R&D pipeline:
- The vaccine candidate VAC-3S, developed by InnaVirVax, should represent a new therapeutic class which aims to preserve and restore the immune system of patients under a therapeutic approach that targets a functional cure goal. Initiated in 2008, development of this first-in-class therapeutic vaccine is currently in its phase II clinical studies.
- The companion test (CO-3S), developed by Diaxonhit in partnership with InnaVirVax, is designed to measure anti-3S antibody levels in patients treated with VAC-3S. It should thus be possible to measure the immune response to VAC-3S.
- The diagnostic test (DIAG-3S), developed by Diaxonhit in partnership with two INSERM research units, seeks to detect the anti-3S antibodies naturally present in HIV-infected patients. This test should constitute an early marker of disease progression.
Others: * On April 28, 2014, InnaVirVax, a biopharmaceutical company specialised in the research and development of therapeutic and diagnostic innovations focused on immune dysregulation, announced that its leadership of the PROTEVIH consortium, which is being funded by the French public agency Bpifrance under its Strategic Industrial Innovation programme. InnaVirVax is receiving support worth €6.3 million for this purpose.
The global budget of the PROTHEVIH programme (PROTECTION of the immune system by DIAGNOSIS and personalised THERAPY targeting the pathogenicity of HIV) is €9.4 million over 5 years, entirely funded by Bpifrance in the form of subsidies and refundable advance payments. Its objective is to respond to unsatisfied medical needs among HIV-infected patients.
Therapeutic area: Infectious diseases
